Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also develo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

One Main Street, 14th Floor, Cambridge, United States

justiceforb_85 Jan. 22 at 12:24 AM

$BDTX love this movement today. Hopefully they find a partner to further advance silevertinib in a P3.

1 · Reply

BillionerOfKing Jan. 20 at 4:54 AM

$BDTX Current Stock Price: $2.57 Contracts to trade: $2.5 BDTX Feb 20 2026 Call Entry: $0.15 Exit: $0.27 ROI: 80% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

100K2022 Jan. 16 at 9:41 PM

$BDTX

0 · Reply

Quantumup Jan. 16 at 12:19 PM

BTIG (a/o Dec. 10),🏁 $AVBP at a Buy rating and a $45 PT. $ORIC $BDTX Cantor (a/o Dec 22),🏁 $AVBP at an Overweight rating. Oppenheimer (a/o Jan. 6), reiterated $AVBP at an Outperform rating and a $44 PT Here's what the Analysts had to say:

0 · Reply

ATLATL Jan. 14 at 3:30 AM

$BDTX I didn't think this would stay at or near cash as long as it has, but I do think momentum will build slowly. Trading this is risky between now and data and/or partnership/pivot. Long term hold here.

0 · Reply

Invest2live Jan. 13 at 5:55 PM

$EXPE 166% already; congrats 🌿🎈 🌿 Checkout $PHR and $BDTX; undervalued. Both have potential to double.

0 · Reply

BearsAreTasty Jan. 12 at 2:40 PM

$BDTX Somebody took a big dump on this stock this morning but it will bounce right back. Thanks for the temporary discount.

1 · Reply

100K2022 Jan. 12 at 2:40 PM

$BDTX news?

0 · Reply

questionable1 Jan. 11 at 5:40 PM

$BDTX

0 · Reply

mdemattia Jan. 10 at 12:49 AM

$BDTX Zach’s just gave BDTX it’s highest rating. Seeking Alpha has BDTX rated 35 out of 466 biotech stocks covered. Got a good feeling.

0 · Reply

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Dec 3, 2025, 7:01 AM EST - 7 weeks ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 7 weeks ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Nov 20, 2025, 8:57 AM EST - 2 months ago

Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout

Nov 6, 2025, 4:01 PM EST - 2 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 7:30 AM EST - 2 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 10, 2025, 4:32 AM EDT - 3 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC CHRS

Aug 25, 2025, 11:13 AM EDT - 5 months ago

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Aug 7, 2025, 7:30 AM EDT - 6 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 10, 2025, 6:38 AM EDT - 8 months ago

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

May 29, 2025, 8:00 AM EDT - 8 months ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 12, 2025, 4:05 PM EDT - 9 months ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 25, 2025, 12:58 AM EDT - 10 months ago

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 19, 2025, 7:00 AM EDT - 11 months ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 13, 2025, 3:47 PM EDT - 11 months ago

Black Diamond Therapeutics: In Decline, But Why?

Mar 6, 2025, 4:01 PM EST - 11 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 30, 2024, 3:07 PM EST - 1 year ago

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 3:24 PM EDT - 1 year ago

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 27, 2024, 10:38 AM EDT - 1 year ago

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 1, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 1 year ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 24, 2024, 11:25 PM EDT - 1 year ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA DFH DHI GE

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 2 years ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 12, 2024, 5:21 PM EST - 2 years ago

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 12, 2023, 8:31 AM EDT - 2 years ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:53 AM EDT - 2 years ago

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Jun 29, 2023, 8:57 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 6:51 PM EDT - 2 years ago

Black Diamond: On Right Track For Possible Accelerated Approval Pathway

Jun 28, 2023, 4:23 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

justiceforb_85 Jan. 22 at 12:24 AM

$BDTX love this movement today. Hopefully they find a partner to further advance silevertinib in a P3.

1 · Reply

BillionerOfKing Jan. 20 at 4:54 AM

0 · Reply

100K2022 Jan. 16 at 9:41 PM

$BDTX

0 · Reply

Quantumup Jan. 16 at 12:19 PM

0 · Reply

ATLATL Jan. 14 at 3:30 AM

0 · Reply

Invest2live Jan. 13 at 5:55 PM

$EXPE 166% already; congrats 🌿🎈 🌿 Checkout $PHR and $BDTX; undervalued. Both have potential to double.

0 · Reply

BearsAreTasty Jan. 12 at 2:40 PM

$BDTX Somebody took a big dump on this stock this morning but it will bounce right back. Thanks for the temporary discount.

1 · Reply

100K2022 Jan. 12 at 2:40 PM

$BDTX news?

0 · Reply

questionable1 Jan. 11 at 5:40 PM

$BDTX

0 · Reply

mdemattia Jan. 10 at 12:49 AM

$BDTX Zach’s just gave BDTX it’s highest rating. Seeking Alpha has BDTX rated 35 out of 466 biotech stocks covered. Got a good feeling.

0 · Reply

100K2022 Jan. 8 at 9:02 PM

$BDTX me Likey!

0 · Reply

100K2022 Jan. 8 at 8:32 PM

$BDTX go green baby!!

0 · Reply

BearsAreTasty Jan. 7 at 7:54 PM

$BDTX Let's get this party started 🎉

0 · Reply

Stock_Squatch_Watcher Jan. 6 at 5:53 AM

$BDTX So undervalued. Cannot understand what the street missed after the P2 presentation, other than basic scientific understanding. 🤦‍♂️ Well, good time to buy. 🦶🏿

1 · Reply

Jafo333isme Jan. 6 at 1:11 AM

$BDTX Up Slow n steady. Some big buys in AH tnite.

0 · Reply

questionable1 Jan. 5 at 8:08 PM

$BDTX

0 · Reply

questionable1 Jan. 3 at 12:49 AM

$BDTX slowly but surely

0 · Reply

MrTumble Jan. 2 at 5:15 PM

$BDTX Double

0 · Reply

BearsAreTasty Jan. 2 at 3:15 PM

$BDTX

0 · Reply

questionable1 Jan. 2 at 2:50 PM

$BDTX

0 · Reply

100K2022 Dec. 30 at 9:14 PM

$BDTX We need some news!!

0 · Reply

Icemanrush16 Dec. 27 at 12:52 PM

$BDTX cash runway of 130M - will get them to late 27 early 28 so no dilution in sight - see targets from analysts, most recent ones. Speculative play with high upside IMO - one positive news about clinical data can change SP in a heart beat. ✌🏼 Firm Rating Price Target Approx. Date Piper Sandler Overweight $9.00 Nov 18, 2025 GuruFocus Stifel Buy $8.00 Dec 2025 http://Investing.com Guggenheim Buy $8.00 Sep 2025 Yahoo Finance Freedom Capital Buy $6.00 Late 2025 http://Investing.com (Consensus Avg.) — ~$9.4 Nov 18, 20

1 · Reply

Market Cap	146.43M
Revenue (ttm)	0.00
Net Income (ttm)	-69.68M
EPS (ttm)	N/A
PE Ratio	6.67
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	573,600
Avg Vol	1,330,038
Day's Range	N/A - N/A
Shares Out	56.98M
Stochastic %K	56%
Beta	3.40
Analysts	Strong Sell
Price Target	$9.29